Exploration of Cytochrome P450 Inhibition Mediated Drug-drug Interaction Potential of Kratom Alkaloids

Overview

Journal Toxicol Lett

Publisher Elsevier

Specialty Toxicology

Date 2019 Nov 11

PMID 31707106

Citations 27

Authors

Shyam H Kamble

Abhisheak Sharma

Tamara I King

Erin C Berthold

Francisco Leon

P Katharina L Meyer

Siva Rama Raju Kanumuri

Lance R McMahon

Christopher R McCurdy

Bonnie A Avery

Affiliations

Soon will be listed here.

Abstract

In vitro cytochrome P450 inhibition of major kratom alkaloids: mitragynine (MTG), speciogynine (SPG), speciocilliatine (SPC), corynantheidine (COR), 7-hydroxymitragynine (7HMG) and paynantheine (PAY) was evaluated using human liver microsomes (HLMs) to understand their drug-drug interaction potential. CYP450 isoform-specific substrates of CYP1A2, 2C8, 2C9, 2C19, 2D6, and 3A4/5 were incubated in HLMs with or without alkaloids. Preliminary CYP450 inhibition (IC) data were generated for each of these isoforms. In addition, the type of inhibition and estimation of the inhibition constants (K) of MTG and COR were determined. Among the tested alkaloids, MTG and COR were potent inhibitors of CYP2D6 (IC, 2.2 and 4.2 μM, respectively). Both MTG and COR exhibited competitive inhibition of CYP2D6 activity and the K were found to be 1.1 and 2.8 μM, respectively. SPG and PAY showed moderate inhibition of CYP2D6 activity. Additionally, moderate inhibitory effects by SPC, MTG, and SPG were observed on CYP2C19 activity. Interestingly, inhibition of only midazolam hydroxylase CYP3A4/5 activity by COR, PAY, and MTG was observed while no inhibitory effect was observed when testosterone was used as a probe substrate. In conclusion, MTG and COR may lead to clinically significant adverse drug interactions upon coadministration of drugs that are substantially metabolized by CYP2D6.

Citing Articles

Inhibitory effects of Kratom constituents, mitragynine and 7-hydroxymitragynine, on 4-methylumbelliferone glucuronidation by human UDP-glucuronosyltransferases.

Uchaipichat V Toxicol Rep. 2025; 14:101951.

PMID: 40026476 PMC: 11872117. DOI: 10.1016/j.toxrep.2025.101951.

Korth toxicity: Experimental findings and future prospects.

Begum T, Arzmi M, Uddin A, Khatib A, Abbas S, Ahmed Q J Taibah Univ Med Sci. 2025; 19(6):1143-1156.

PMID: 39802218 PMC: 11720435. DOI: 10.1016/j.jtumed.2024.12.002.

Kratom: A Narrative Review of the Possible Clinical Uses and Dangers of This Opioid-Like Plant.

Edinoff A, Kaufman S, Mahoney T, Upshaw W, Gong J, Cornett E Cureus. 2024; 16(11):e73058.

PMID: 39640144 PMC: 11619718. DOI: 10.7759/cureus.73058.

Effects of polyphenols extracted from Keemun black tea on CYP450s activity and molecular mechanisms.

Zuo D, Lv L, Ren H, Sun H Food Sci Nutr. 2024; 12(10):7306-7315.

PMID: 39479673 PMC: 11521629. DOI: 10.1002/fsn3.4319.

Drug-drug interactions of plant alkaloids derived from herbal medicines on the phase II UGT enzymes: an introductory review.

Gunasaykaran S, Chear N, Ismail S, Mohammad N, Murugaiyah V, Ramanathan S Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1447-1464.

PMID: 39325152 DOI: 10.1007/s00210-024-03418-8.

References

Walsky R, Obach R, Gaman E, Gleeson J, Proctor W . Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos. 2004; 33(3):413-8. DOI: 10.1124/dmd.104.002766. View

Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D . Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands. J Med Chem. 2002; 45(9):1949-56. DOI: 10.1021/jm010576e. View

Olsen E, ODonnell J, Mattson C, Schier J, Wilson N . Notes from the Field: Unintentional Drug Overdose Deaths with Kratom Detected - 27 States, July 2016-December 2017. MMWR Morb Mortal Wkly Rep. 2019; 68(14):326-327. PMC: 6459583. DOI: 10.15585/mmwr.mm6814a2. View

Stresser D, Blanchard A, Turner S, Erve J, Dandeneau A, Miller V . Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos. 2000; 28(12):1440-8. View

Boyer E, Babu K, Adkins J, McCurdy C, Halpern J . Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008; 103(6):1048-50. PMC: 3670991. DOI: 10.1111/j.1360-0443.2008.02209.x. View

Veltri C, Grundmann O . Current perspectives on the impact of Kratom use. Subst Abuse Rehabil. 2019; 10:23-31. PMC: 6612999. DOI: 10.2147/SAR.S164261. View

Gershman K, Timm K, Frank M, Lampi L, Melamed J, Gerona R . Deaths in Colorado Attributed to Kratom. N Engl J Med. 2019; 380(1):97-98. PMC: 6688840. DOI: 10.1056/NEJMc1811055. View

Kamble S, Sharma A, King T, Leon F, McCurdy C, Avery B . Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of (kratom). Xenobiotica. 2018; 49(11):1279-1288. DOI: 10.1080/00498254.2018.1552819. View

Cho D, Bae S, Lee J, Kim Y, Kim B, Bae S . Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes. Drug Metab Dispos. 2013; 42(1):33-9. DOI: 10.1124/dmd.113.054296. View

10.

Hemby S, McIntosh S, Leon F, Cutler S, McCurdy C . Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2018; 24(5):874-885. DOI: 10.1111/adb.12639. View

11.

Aarons L, Rowland M . Kinetics of drug displacement interactions. J Pharmacokinet Biopharm. 1981; 9(2):181-90. DOI: 10.1007/BF01068081. View

12.

Prozialeck W, Avery B, Boyer E, Grundmann O, Henningfield J, Kruegel A . Kratom policy: The challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019; 70:70-77. PMC: 7881941. DOI: 10.1016/j.drugpo.2019.05.003. View

13.

Kruegel A, Gassaway M, Kapoor A, Varadi A, Majumdar S, Filizola M . Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc. 2016; 138(21):6754-64. PMC: 5189718. DOI: 10.1021/jacs.6b00360. View

14.

Lin J, Lu A . Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998; 35(5):361-90. DOI: 10.2165/00003088-199835050-00003. View

15.

Wienkers L, Heath T . Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005; 4(10):825-33. DOI: 10.1038/nrd1851. View

16.

Swogger M, Hart E, Erowid F, Erowid E, Trabold N, Yee K . Experiences of Kratom Users: A Qualitative Analysis. J Psychoactive Drugs. 2015; 47(5):360-7. DOI: 10.1080/02791072.2015.1096434. View

17.

Bjornsson T, Callaghan J, Einolf H, Fischer V, Gan L, Grimm S . The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003; 31(7):815-32. DOI: 10.1124/dmd.31.7.815. View

18.

Kenworthy K, Bloomer J, Clarke S, Houston J . CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol. 1999; 48(5):716-27. PMC: 2014361. DOI: 10.1046/j.1365-2125.1999.00073.x. View

19.

Paine M, Hart H, Ludington S, Haining R, Rettie A, Zeldin D . The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006; 34(5):880-6. PMC: 2222892. DOI: 10.1124/dmd.105.008672. View

20.

Sharma A, Kamble S, Leon F, Chear N, King T, Berthold E . Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2019; 11(8):1162-1171. PMC: 7927418. DOI: 10.1002/dta.2604. View